PainChek

PainChek R&D / Revenue

The R&D to Revenue Ratio of PainChek (PCK.AX) as of Nov 11, 2026 is 112.39 %. In the previous year, R&D to Revenue Ratio was 171.08 % — a change of -34.30% (lower).

R&D / Revenue

112.39 %

YoY

-34.30%

Last updated:

R&D to Revenue Ratio of PainChek is 2025 112.39 % . R&D to Revenue Ratio of PainChek was 2024 171.08 % . It decreases by -34.30% lower compared to the previous year.

The PainChek R&D / Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D / Revenue
Date
R&D / Revenue
Jan 1, 2018
3,355.17 AUD
Jan 1, 2019
879.28 AUD
Jan 1, 2020
914.79 AUD
Jan 1, 2021
1,234.70 AUD
Jan 1, 2022
240.23 AUD
Jan 1, 2023
195.81 AUD
Jan 1, 2024
171.08 AUD
Jan 1, 2025
112.39 AUD
The PainChek R&D / Revenue history
YEARR&D / RevenueYoY
112.39 %-34.30%
171.08 %-12.63%
195.81 %-18.49%
240.23 %-80.54%
1,234.70 %+34.97%
914.79 %+4.04%
879.28 %-73.79%
3,355.17 %+27.10%
2,639.89 %+23.03%
2,145.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PainChek Stock analysis

What does PainChek do? PainChek Ltd. develops and commercializes mobile medical device applications, focusing on pain assessment for individuals unable to communicate with carers. The PainChek Universal combines the PainChek Application with the numerical rating scale (NRS), using artificial intelligence and facial recognition to detect pain in non-verbal patients. It provides a point-of-care solution that offers objectivity and consistency in pain assessments, supporting both non-verbal and self-reporting individuals through integrated tools. Healthcare providers and care facilities purchase PainChek Universal to enhance pain management protocols for patients with communication difficulties. The PainChek Application utilizes artificial intelligence and facial recognition technology to assess pain without relying on patient self-reporting, making it suitable for those with cognitive or physical impairments. PainChek Universal integrates the NRS for patients who can self-report, ensuring a comprehensive approach to pain evaluation across varying patient capabilities. This dual functionality allows healthcare professionals to apply consistent assessment standards regardless of a patient's ability to communicate. PainChek Ltd. generates revenue through the commercialization of its mobile medical device applications, specifically targeting healthcare providers and care facilities that require standardized pain assessment tools. The company’s products are designed to address the needs of patients who cannot communicate pain, thereby filling a critical gap in healthcare services. By offering a unified solution that combines AI-driven detection with traditional rating scales, PainChek Universal meets the demands of modern healthcare environments seeking objective and reliable pain management solutions. PainChek is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PainChek stock

R&D to Revenue Ratio of PainChek is 112.39 % in 2025.

R&D to Revenue Ratio of PainChek changed from 171.08 % to 112.39 %, representing a -34.30% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D to Revenue Ratio PainChek since 2006 – with annual values, charts, and detailed analysis.

The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.

A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's PainChek with sector peers and the industry average to assess whether it is attractive.

To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — PainChek

All Key Metrics — PainChek